# Ipsoprubart

Source: https://onco.cc/drugs/ipsoprubart/  
OnCo record `ipsoprubart` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ipsoprubart is an experimental antibody from Electra Therapeutics, in phase 1 trials for relapsed or refractory T-cell and NK-cell cancers.

## Summary

Ipsoprubart (ELA026) is a monoclonal antibody from Electra Therapeutics. Binds SIRP-alpha (SIRPA) and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells to remove activated immune cells that drive disease. Its lead use is secondary haemophagocytic lymphohistiocytosis, an immune disorder that is not a cancer, in a phase 2/3 study. Its cancer use is a phase 1 study (NCT07465835) in relapsed or refractory T-cell and NK-cell malignancies. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: ELA026
- Tags: pipeline; ctgov-ingest
- Code: ELA026
- Modality: Monoclonal antibody
- Mechanism: Binds SIRP-alpha (SIRPA) and SIRP-beta1 on myeloid cells and SIRP-gamma on T cells to remove activated immune cells that drive disease.

## Sources

- Electra Therapeutics ipsoprubart: https://electra-therapeutics.com/ipsoprubart/
- Electra Therapeutics prospectus (424B4), September 2026: https://www.sec.gov/Archives/edgar/data/2088082/000119312526395670/d61940d424b4.htm
- ClinicalTrials.gov NCT07465835: https://clinicaltrials.gov/study/NCT07465835

## Connected records

- targets: [SIRPA](https://onco.cc/targets/sirpa/)
- companies: [Electra Therapeutics](https://onco.cc/companies/electra-therapeutics/)
- trials: [A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)](https://onco.cc/trials/nct07465835/)

---
JSON: https://onco.cc/api/v1/entities/ipsoprubart.json